<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3569">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04613986</url>
  </required_header>
  <id_info>
    <org_study_id>SD01</org_study_id>
    <nct_id>NCT04613986</nct_id>
  </id_info>
  <brief_title>Therapeutic Plasma Exchange as an Adjunctive Strategy to Treat Coagulopathy and Inflammation in Severe Covid-19</brief_title>
  <acronym>PExCoV</acronym>
  <official_title>Randomized, Prospective, Open-label, Controlled Parallel-group Trial Investigating the Efficacy of Therapeutic Plasma Exchange as an Adjunctive Strategy to Treat the Systemic Inflammatory Response Against SARS-CoV2 and the Associated Coagulopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized controlled trial to analyse adjuvant therapeutic plasma exchange (TPE) in severe&#xD;
      Covid-19 associated coagulopathy and systemic inflammation compared to current standard of&#xD;
      care (SOC).&#xD;
&#xD;
      A total of three TPEs (d1, 3, 5) will be performed in the intervention group. Primary&#xD;
      endpoint is the reversibility of relative ADAMTS13 deficiency (indicated by the change in&#xD;
      ADAMTS13 / VWF:Ag ratio from day 1 to 7).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>relative ADAMTS13 deficiency</measure>
    <time_frame>day 1 to 7</time_frame>
    <description>ADAMTS13 / VWF:Ag</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Severe Covid-19</condition>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care according to our current in house SOP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care according to our current in house SOP + Therapeutic Plasmaexchange (d1, 3, 5)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>therapeutic plasmaexchnage</intervention_name>
    <description>established method to exchange plasma (in order to remove injurious disease mediators, e.g. antibodies) or to replace consumed factors (e.g. vWF cleaving proteases)</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Proven SARS-CoV2 infection&#xD;
&#xD;
          -  Severe Covid-19 (indicated by respiratory failure requiring invasive mechanical&#xD;
             ventilation)&#xD;
&#xD;
          -  Evidence of coagulopathy (indicated by D-dimer &gt; 10 mg/L)&#xD;
&#xD;
          -  Evidence of systemic inflammation (CRP &gt; 100 mg/L , ferritin &gt; 500 ng/mL)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  â€¢ Participation in another study with investigational drug within the 30 days&#xD;
             preceding and during the present study,&#xD;
&#xD;
               -  Previous enrolment into the current study.&#xD;
&#xD;
               -  Extra corporeal membrane oxygenation (ECMO)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

